Abstract:The chemokine CXCL12 and its G protein-coupled receptor (GPCR) CXCR4 are high-priority clinical targets because of their involvement in metastatic cancers (also implicated in autoimmune disease and cardiovascular disease). Because chemokines interact with two distinct sites to bind and activate their receptors, both the GPCRs and chemokines are potential targets for small molecule inhibition. A number of chemokines have been validated as targets for drug development, but virtually all drug discovery efforts focus on the GPCRs. However, all CXCR4 receptor antagonists with the exception of MSX-122 have failed in clinical trials due to unmanageable toxicities, emphasizing the need for alternative strategies to interfere with CXCL12/CXCR4-guided metastatic homing. Although targeting the relatively featureless surface of CXCL12 was presumed to be challenging, focusing efforts at the sulfotyrosine (sY) binding pockets proved successful for procuring initial hits. Using a hybrid structure-based in silico/NMR screening strategy, we recently identified a ligand that occludes the receptor recognition site. From this initial hit, we designed a small fragment library containing only nine tetrazole derivatives using a fragment-based and bioisostere approach to target the sY binding sites of CXCL12. Compound binding modes and affinities were studied by 2D NMR spectroscopy, X-ray crystallography, molecular docking and cell-based functional assays. Our results demonstrate that the sY binding sites are conducive to the development of high affinity inhibitors with better ligand efficiency (LE) than typical protein-protein interaction inhibitors (LE ≤ 0.24). Our novel tetrazole-based fragment 18 was identified to bind the sY21 site with a K(d) of 24 μM (LE = 0.30). Optimization of 18 yielded compound 25 which specifically inhibits CXCL12-induced migration with an improvement in potency over the initial hit 9. The fragment from this library that exhibited the highest affinity and ligand efficiency (11: K(d) = 13 μM, LE = 0.33) may serve as a starting point for development of inhibitors targeting the sY12 site.

Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines

Design, Synthesis, and Structure-Activity-relationship of a Novel Series of CXCR4 Antagonists.

Design, Synthesis, and Evaluation of Novel CXCR4 Antagonists Based on an Aminoquinoline Template.

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands

Structural Optimization of Aminopyrimidine-Based CXCR4 Antagonists.

Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists.

Design and Synthesis of Tri‐substituted Chiral Pyrrolidin‐2‐one Derivatives As CCR4 Antagonists

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Design, Synthesis, and Biological Characterization of Novel PEG-linked Dimeric Modulators for CXCR4.

Synthesis, Structure–Activity Relationship Studies, and ADMET Properties of 3‐aminocyclohex‐2‐en‐1‐ones As Chemokine Receptor 2 (CXCR2) Antagonists

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs

Structural Analysis of a Novel Small Molecule Ligand Bound to the CXCL12 Chemokine

Design, Synthesis and SAR Study of Novel Trisubstituted Pyrimidine Amide Derivatives As CCR4 Antagonists

Computational Analysis of the Structural Mechanism of Inhibition of Chemokine Receptor CXCR4 by Small Molecule Antagonists

Fragment-based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction.

The Chemical Diversity and Structure-Based Evolution of Non-Peptide CXCR4 Antagonists with Diverse Therapeutic Potential.

Discovery of 1,5-Dihydro-4<i>H</i>-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2

A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist

Structure-Based Development of Antagonists for Chemokine Receptor CXCR4